{"url_path":"/sec/pmvp/8-k/2026-06-05/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-05","source_url":"https://www.sec.gov/Archives/edgar/data/1699382/0001193125-26-258466-index.html","accession_number":"0001193125-26-258466","cik":"0001699382","ticker":"PMVP","issuer_name":"PMV Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1699382/0001193125-26-258466-index.html","primary_entity_key":"0001699382","primary_entity_name":"PMV Pharmaceuticals, Inc."},"word_count":408,"has_tables":true,"body_markdown":"Item 5.07.\n\nSubmission of Matters to a Vote of Security Holders.\n\nOn June 4, 2026, PMV Pharmaceuticals, Inc. (the “Company”) held its virtual 2026 Annual Meeting of Stockholders (the “Annual Meeting”) exclusively online via live webcast. The stockholders voted on the following proposals at the Annual Meeting:\n\nProposal 1. Election of Directors\n\nThe Company’s stockholders elected the two persons listed below as Class III Directors, each to serve until the Company’s 2029 annual meeting of stockholders and until their respective successors has been duly elected and qualified, or until the earlier of the respective director’s death, resignation or removal. The final voting results are as follows:\n\n \n\n \n  \nFOR\n  \nWITHHELD\n  \nBROKER\nNON-VOTE\n\nDavid H. Mack, Ph.D.\n\n  \n15,693,907\n  \n6,248,461\n  \n6,975,412\n\nLaurie Stelzer\n\n  \n11,261,111\n  \n10,681,257\n  \n6,975,412\n\nProposal 2. Non-Binding Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers\n\nThe Company’s stockholders approved, on a non-binding advisory basis, the compensation paid to its named executive officers as described in the Company’s definitive proxy statement on Schedule 14A, filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 22, 2026 (the “Proxy Statement”). The final voting results are as follows:\n\n \n\nFOR\n \nAGAINST\n \nABSTAIN\n \nBROKER NON-VOTE\n\n15,015,578\n \n6,468,718\n \n458,072\n \n6,975,412\n\nConsistent with the recommendation of the Company’s Board of Directors and based on the Company’s stockholders’ approval at the Company’s 2022 annual meeting of stockholders, held on June 2, 2022, the Company conducts non-binding advisory votes on the compensation of its named executive officers every year. This policy will remain in effect until the next non-binding advisory stockholder vote on the frequency of future stockholder advisory votes on the compensation of the Company’s named executive officers, expected to be held at the Company’s 2028 annual meeting of stockholders.\n\nProposal 3. Ratification of Independent Registered Public Accounting Firm\n\nThe Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows:\n\n \n\nFOR\n \nAGAINST\n \nABSTAIN\n\n28,379,108\n \n536,302\n \n2,370\n\nFor more information about the foregoing proposals, see the Proxy Statement as filed with the SEC.\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\nPMV PHARMACEUTICALS, INC.\n\nBy:\n \n\n/s/ Michael Carulli\n\n \nMichael Carulli\n\n \nChief Financial Officer\n\nDate: June 5, 2026"}